Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gene therapy trial offers hope for cure of devastating childhood disease

NCT ID NCT06149403

Summary

This study is testing whether a new gene therapy called OTL-203 works better and is safer than the current standard treatment (stem cell transplant) for children with Hurler syndrome. Hurler syndrome is a severe genetic disorder that causes progressive damage to the brain, bones, and organs. The trial will follow 40 children for up to 5 years to see which treatment helps them live longer without major complications.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MPS-IH (HURLER SYNDROME) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Manchester University NHS Foundation Trust Blood and Marrow Transplant Programme, Royal Manchester Children's Hospital

    Manchester, M13 9WL, United Kingdom

  • Ospedale San Raffaele

    Milan, 20131, Italy

  • Princess Maxima Center

    Utrecht, 3584 CS, Netherlands

  • UMC Utrecht

    Utrecht, 3584 CX, Netherlands

  • University of Minnesota, Pediatrics

    Minneapolis, Minnesota, 55455, United States

Conditions

Explore the condition pages connected to this study.